Lineage Cell Therapeutics
LCTX
LCTX
96 hedge funds and large institutions have $161M invested in Lineage Cell Therapeutics in 2017 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 39 increasing their positions, 18 reducing their positions, and 5 closing their positions.
Holders
96
Holders Change
+4
Holders Change %
+4.35%
% of All Funds
2.39%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
14
Increased
39
Reduced
18
Closed
5
Calls
$3K
Puts
$103K
Net Calls
-$100K
Net Calls Change
-$81K
Top Buyers
1 |
1
BlackRock
New York
|
$16.9M |
2 |
BC
2
Broadwood Capital
New York
|
$93.6M |
3 |
PGP
3
Prescott General Partners
Boca Raton,
Florida
|
$6.39M |
4 |
4
Geode Capital Management
Boston,
Massachusetts
|
$3.6M |
5 |
5
Vanguard Group
Malvern,
Pennsylvania
|
$10.9M |